Theratechnologies Inc. Cash Flow Conversion Efficiency
Theratechnologies Inc. cash flow conversion efficiency. Based on the latest financial reports, Theratechnologies Inc. (TH) has a cash flow conversion efficiency ratio of -0.095x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.66 Million ≈ $1.92 Million USD) by net assets (CA$-27.92 Million ≈ $-20.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Theratechnologies Inc. (1996–2024)
Cash flow conversion efficiency of Theratechnologies Inc. from 1996 to 2024. This chart illustrates how Theratechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Theratechnologies Inc. stock price for real-time trading data and today's change.
Theratechnologies Inc. Cash Flow Conversion Ratio Explained
Theratechnologies Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Theratechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theratechnologies Inc. ranked by their cash flow conversion efficiency. Also see Theratechnologies Inc. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UniTest Incorporation
KQ:086390
|
-0.085x |
|
Korea Real Estate Investment & Trust Co Ltd
KO:034830
|
-0.011x |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
0.021x |
|
Imagesat International ISI Ltd
TA:ISI
|
0.108x |
|
Gala Precision Engineering
NSE:GALAPREC
|
0.025x |
|
Bank Agris Tbk
JK:AGRS
|
0.027x |
|
PChome Online
TWO:8044
|
0.039x |
|
Promate Solutions
TWO:6577
|
0.084x |
Annual Cash Flow Conversion Efficiency for Theratechnologies Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of Theratechnologies Inc. from 1996 to 2024. Review Theratechnologies Inc. free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | CA$-25.27 Million ≈ $-18.28 Million |
CA$2.38 Million ≈ $1.72 Million |
-0.094x | -134.60% |
| 2023-11-30 | CA$-20.87 Million ≈ $-15.10 Million |
CA$-5.68 Million ≈ $-4.11 Million |
0.272x | -58.20% |
| 2022-11-30 | CA$-22.57 Million ≈ $-16.33 Million |
CA$-14.69 Million ≈ $-10.63 Million |
0.651x | +179.85% |
| 2021-11-30 | CA$17.76 Million ≈ $12.85 Million |
CA$-14.48 Million ≈ $-10.47 Million |
-0.815x | +80.61% |
| 2020-11-30 | CA$3.22 Million ≈ $2.33 Million |
CA$-13.55 Million ≈ $-9.80 Million |
-4.204x | -2978.87% |
| 2019-11-30 | CA$24.83 Million ≈ $17.96 Million |
CA$-3.39 Million ≈ $-2.45 Million |
-0.137x | -1331.40% |
| 2018-11-30 | CA$35.05 Million ≈ $25.36 Million |
CA$-334.40K ≈ $-241.90K |
-0.010x | -116.76% |
| 2017-11-30 | CA$33.51 Million ≈ $24.24 Million |
CA$1.91 Million ≈ $1.38 Million |
0.057x | -43.11% |
| 2016-11-30 | CA$20.02 Million ≈ $14.48 Million |
CA$2.00 Million ≈ $1.45 Million |
0.100x | -71.72% |
| 2015-11-30 | CA$14.98 Million ≈ $10.83 Million |
CA$5.30 Million ≈ $3.83 Million |
0.354x | +134.63% |
| 2014-11-30 | CA$6.87 Million ≈ $4.97 Million |
CA$-7.02 Million ≈ $-5.08 Million |
-1.022x | -144.46% |
| 2013-11-30 | CA$17.45 Million ≈ $12.62 Million |
CA$-7.29 Million ≈ $-5.28 Million |
-0.418x | +39.39% |
| 2012-11-30 | CA$22.82 Million ≈ $16.51 Million |
CA$-15.74 Million ≈ $-11.39 Million |
-0.690x | +7.92% |
| 2011-11-30 | CA$35.20 Million ≈ $25.46 Million |
CA$-26.36 Million ≈ $-19.07 Million |
-0.749x | -1459.83% |
| 2010-11-30 | CA$51.65 Million ≈ $37.36 Million |
CA$2.84 Million ≈ $2.06 Million |
0.055x | -58.09% |
| 2009-11-30 | CA$40.70 Million ≈ $29.44 Million |
CA$5.35 Million ≈ $3.87 Million |
0.131x | +114.60% |
| 2008-11-30 | CA$37.80 Million ≈ $27.35 Million |
CA$-34.03 Million ≈ $-24.62 Million |
-0.900x | -83.28% |
| 2007-11-30 | CA$65.94 Million ≈ $47.70 Million |
CA$-32.39 Million ≈ $-23.43 Million |
-0.491x | +5.50% |
| 2006-11-30 | CA$38.96 Million ≈ $28.18 Million |
CA$-20.25 Million ≈ $-14.65 Million |
-0.520x | -487.37% |
| 2005-11-30 | CA$41.96 Million ≈ $30.35 Million |
CA$-3.71 Million ≈ $-2.69 Million |
-0.088x | +74.68% |
| 2004-11-30 | CA$53.02 Million ≈ $38.35 Million |
CA$-18.53 Million ≈ $-13.40 Million |
-0.349x | -6.85% |
| 2003-11-30 | CA$64.48 Million ≈ $46.65 Million |
CA$-21.09 Million ≈ $-15.26 Million |
-0.327x | -72.10% |
| 2002-11-30 | CA$79.51 Million ≈ $57.52 Million |
CA$-15.11 Million ≈ $-10.93 Million |
-0.190x | -58.13% |
| 2001-11-30 | CA$70.95 Million ≈ $51.32 Million |
CA$-8.53 Million ≈ $-6.17 Million |
-0.120x | -1.33% |
| 2000-11-30 | CA$38.53 Million ≈ $27.87 Million |
CA$-4.57 Million ≈ $-3.31 Million |
-0.119x | +40.93% |
| 1999-11-30 | CA$16.91 Million ≈ $12.23 Million |
CA$-3.40 Million ≈ $-2.46 Million |
-0.201x | +38.66% |
| 1998-11-30 | CA$10.94 Million ≈ $7.91 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.327x | +35.81% |
| 1997-11-30 | CA$7.03 Million ≈ $5.08 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.510x | -102.72% |
| 1996-11-30 | CA$11.80 Million ≈ $8.54 Million |
CA$-2.97 Million ≈ $-2.15 Million |
-0.252x | -- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more